As interest in device-based hypertension therapies continues to grow, the U.S. FDA has given Valencia Technologies Corp. the go-ahead, as soon as certain conditions are met, to start an investigational device exemption (IDE) pivotal study of its nickel-sized neurostimulator for drug-resistant hypertension. The device is designed to use low-duty cycle current to stimulate the median nerve once a week for 30 minutes – without any leads.
About 15 years ago Chris Toumazou imagined that if the electronics industry could scale down electronic circuits so that they were smaller, faster, and cheaper to produce – paving the way for consumer-based products like mobile phones and tablets – it might be possible to apply microchips to the health care industry. Inspired by that idea, Toumazou, a professor at Imperial College London, invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive...
About 15 years ago Chris Toumazou imagined that if the electronics industry could scale down electronic circuits so that they were smaller, faster, and cheaper to produce – paving the way for consumer-based products like mobile phones and tablets – it might be possible to apply microchips to the health care industry.
Wednesday was a great day for the diabetes community, Richard Bergenstal, a research clinician at the International Diabetes Center at Park Nicollet, told Medical Device Daily, soon after the FDA approved the first commercial device often referred to as an artificial pancreas. Medtronic plc's Minimed 670g hybrid closed loop system is now approved for patients 14 years of age and older with type 1 diabetes. The device is designed to adjust insulin levels with little or no input from the user by measuring glucose levels every five minutes. The regulatory milestone came about three...
Wednesday was a great day for the diabetes community, Richard Bergenstal, a research clinician at the International Diabetes Center at Park Nicollet, told Medical Device Daily, soon after the FDA approved the first commercial device often referred to as an artificial pancreas.
Natus Medical Inc.'s stock (NASDAQ; BABY) slipped 9.73 percent ($4.28) after the company said it expected a revenue shortfall for the third quarter, primarily due to a shipping hold, but also shared plans to buy GN Otometrics from GN Store Nord A/S in a $145 million cash deal. Natus, of Pleasanton, Calif., said the acquisition of Otometrics, which makes hearing diagnostic and balance assessment equipment and has contributed about $110 million in annual revenue to Taastrup, Denmark-based GN, will expand its offering with "very little overlap." The deal is expected to close by the...
Natus Medical Inc.'s stock (NASDAQ; BABY) slipped 9.73 percent ($4.28) after the company said it expected a revenue shortfall for the third quarter, primarily due to a shipping hold, but also shared plans to buy GN Otometrics from GN Store Nord A/S in a $145 million cash deal.
Abbott Laboratories' divestiture of its optics business could indicate that the company is ready to bite the figurative Alere Inc. bullet and move forward with that $5.8 billion acquisition – but not necessarily.
